Ani Pharmaceuticals INC Form 4 insider transactions

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports disposition of shares for tax purposes related to vesting of restricted stock.

Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, reports the disposal of shares to cover tax obligations related to vesting restricted stock.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to the vesting of restricted stock.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, sold 1,000 shares of common stock on March 7, 2025, at a price of $60.86 per share, according to a Form 4 filing with the SEC.

Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, reported the acquisition and disposal of company stock on March 5, 2025, including the exercise of stock options and sale of shares.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, reports the withholding of 1,099 common stock shares for tax purposes related to the vesting of restricted stock on February 28, 2025.

Thomas Andrew Rowland, SVP at ANI Pharmaceuticals, disposed of 627 shares to cover tax obligations related to vesting restricted stock.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to vesting restricted stock.

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports disposition of shares for tax purposes following vesting of restricted stock.

Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, disposed of 1,570 shares of common stock to cover tax obligations related to vesting restricted stock.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, reports disposition of shares for tax purposes following vesting of restricted stock.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, reported a transaction involving the withholding of shares for tax purposes related to the vesting of restricted stock.

Krista Davis, SVP, CHIEF HR OFFICER of ANI Pharmaceuticals, sold 1,000 shares of common stock at $60.2 per share on February 21, 2025, according to a Form 4 filing.

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, reports acquiring shares of common stock through restricted stock awards and performance stock units.

Thomas Rowland, SVP at ANI Pharmaceuticals, reports acquisition and disposal of company stock, including restricted stock awards and shares withheld for tax purposes.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports acquisition and disposal of company stock related to vesting of restricted stock and performance stock units.

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports acquisition and disposal of common stock and shares withheld for tax purposes.

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, reports acquisition and disposal of common stock due to vesting of restricted stock and performance stock units, as well as shares withheld for tax purposes.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, reports acquiring shares through restricted stock awards and performance stock units.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, reports acquisition and disposal of company stock, including vesting of restricted stock and performance stock units, as well as a sale under a 10b5-1 trading plan.

Stephen Carey, SVP & CFO of ANI Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 400 shares of common stock on January 13, 2025, at a price of $53.92 per share.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, sold 7,500 shares of common stock at an average price of $55.79 on December 17, 2024.

Meredith Cook, Senior VP, General Counsel & Secretary of ANI Pharmaceuticals, sold 250 shares of common stock at $56.24 per share under a pre-arranged 10b5-1 trading plan.

Krista Davis, SVP and Chief HR Officer at ANI Pharmaceuticals, sold 1,000 shares of common stock at $60 per share on December 11, 2024, under a pre-arranged 10b5-1 trading plan.

ANI Pharmaceuticals CEO, Nikhil Lalwani, exercised stock options and sold shares on November 26, 2024.

An ANI Pharmaceuticals executive, Thomas Andrew Rowland, sold 867 shares of common stock to cover tax obligations related to vesting restricted stock.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 6,500 shares of common stock at a price of $57.7 per share on November 15, 2024.

Meredith Cook, Senior VP, General Counsel & Secretary of ANI Pharmaceuticals, sold 250 shares of common stock at $61.36 per share under a pre-arranged 10b5-1 trading plan.